Compounded GLP-1 safety checklists: what's real, what's not

What did @betterlivingforeveryone actually say?

Tiffany, a physician assistant, laid out three questions to ask before ordering compounded GLP-1 medications: whether the pharmacy is 503A or 503B certified, what the Beyond Use Date (BUD) is and whether it has been extended via third-party testing, and where the Active Pharmaceutical Ingredient (API) comes from. She also said compounded pharmacies are "never regulated by the FDA" and framed this as a jurisdictional fact rather than a safety concern. She closed by saying patients should receive dosing instructions in units from a provider.

The framing is practical and aimed at people who cannot access brand-name GLP-1s through insurance. That context matters. This is not a video telling people compounded drugs are equivalent to branded products. It is, broadly, a consumer-protection checklist, and that is a reasonable thing to make.

Does the science back this up?

The 503A versus 503B distinction is real and well-documented, but the regulatory picture is more complicated than she described. The FDA does have oversight authority over compounding pharmacies, particularly 503Bs, which the agency inspects directly.

503B outsourcing facilities are registered with the FDA and subject to current Good Manufacturing Practice (cGMP) standards, meaning federal inspection is part of the deal. 503A pharmacies are primarily regulated by state boards of pharmacy, but the FDA retains authority to act on them under certain conditions, including when there are safety concerns or interstate distribution issues. The FDA has issued warning letters and taken enforcement actions against 503A pharmacies. Saying the FDA has no jurisdiction is an oversimplification that could give patients false confidence about 503A facilities.

On API sourcing, the claim that compounded pharmacies source only from FDA-registered manufacturers is accurate in principle. The FDA requires that bulk drug substances used in compounding come from FDA-registered facilities. However, enforcement gaps exist. A 2023 FDA review of compounded semaglutide products identified formulations containing semaglutide sodium and acetate salts, which are not the same as pharmaceutical-grade semaglutide base, raising real questions about API equivalence and bioavailability.

What did they get wrong (or right)?

The FDA jurisdiction claim is the biggest factual problem here. Saying the FDA does not regulate compounding pharmacies "because it's just not under their jurisdiction" is inaccurate for 503B facilities and misleading for 503A facilities. The FDA absolutely has authority to act on compounders and has done so repeatedly.

What she got right: the 503A versus 503B distinction is a legitimate and useful framework for patients. The BUD guidance is sound. Third-party testing for extended dating is a real practice and asking about it is reasonable consumer due diligence. The point about dosing instructions in units is important because syringe-based dosing errors have been documented with compounded injectable medications, including a 2023 FDA safety communication specifically about insulin and other injectables where unit confusion led to dosing errors.

She also deserves credit for saying "price is not everything" and framing this around safety rather than cost savings. That is a more responsible position than much of what circulates in this space.

What should you actually know?

Compounded GLP-1 medications became widely available during FDA-declared shortage periods for semaglutide and tirzepatide. The FDA removed semaglutide from the shortage list in early 2025, which has significant legal implications for compounding going forward. Compounders can no longer cite shortage status as a legal basis for producing copies of FDA-approved drugs like Wegovy or Ozempic.

This changes the legal landscape for patients currently using compounded semaglutide. It does not mean their medication is immediately unsafe, but it does mean the regulatory and legal basis for their pharmacy's continued production may be narrowing. Patients should ask their provider directly about this shift.

The core checklist in this video is useful but incomplete. Beyond 503A or 503B status, patients should ask whether the pharmacy has a certificate of analysis (COA) from an independent lab confirming potency and purity of the specific lot they received. Lot-specific testing, not just facility certification, is what actually tells you what is in the vial.